There is no single “best” hormone therapy for breast cancer. The right choice depends on whether you are premenopausal or postmenopausal, how advanced your cancer is, and specific features of your tumor. What is consistent across the research: hormone therapy reduces the risk of recurrence by roughly 30% compared to no treatment, and all three major classes of these drugs have decades of evidence behind them.
About 70% to 80% of breast cancers are hormone receptor-positive, meaning the cancer cells use estrogen to grow. Hormone therapy works by cutting off that fuel supply. The specific way it does that, and which drug your oncologist recommends, comes down to your individual situation.
The Three Main Types of Hormone Therapy
Hormone therapies for breast cancer fall into three categories, each with a different mechanism for blocking estrogen’s effect on cancer cells.
Selective estrogen receptor modulators (SERMs) attach to estrogen receptors on breast cancer cells, physically blocking estrogen from reaching them. Tamoxifen is the most widely used SERM. It blocks estrogen in breast tissue but acts like estrogen in other parts of the body, such as bone, which is why it doesn’t cause bone loss the way other therapies can.
Aromatase inhibitors (AIs) work differently. Instead of blocking the receptor, they shut down the enzyme your body uses to produce estrogen outside the ovaries, primarily in fat tissue. The three AIs used in breast cancer are anastrozole, exemestane, and letrozole. A large phase 3 trial comparing all three found no meaningful difference between them: five-year disease-free survival was 90.0% with anastrozole, 89.4% with letrozole, and 88.0% with exemestane. Your oncologist may choose one over another based on your side effect profile or other health conditions, not because one is clearly superior.
Selective estrogen receptor degraders (SERDs) go a step further. They bind to estrogen receptors and destroy them entirely, rather than just blocking them. Fulvestrant is the most established SERD and is given as a monthly injection. It is primarily used in advanced or metastatic breast cancer rather than early-stage disease.
Menopausal Status Drives the Decision
Your menopausal status is the single biggest factor in determining which therapy you’ll be offered. Aromatase inhibitors only work when the ovaries are no longer the main source of estrogen, which is why they are the preferred first-line treatment for postmenopausal women. Compared to tamoxifen, AIs reduce the annual risk of recurrence by about 30% and cut 10-year breast cancer mortality by roughly 15% in this group.
For premenopausal women with lower-risk cancers (small tumors, low grade, no chemotherapy needed), tamoxifen alone performs well. The SOFT and TEXT trials showed that tamoxifen alone gave an eight-year freedom from distant recurrence above 97% in this group.
Premenopausal women with higher-risk disease, such as stage II or III cancers, benefit from a more aggressive approach: ovarian function suppression combined with an aromatase inhibitor. This combination produced a 10% to 15% absolute improvement in eight-year freedom from distant recurrence compared to tamoxifen alone. Ovarian function suppression uses injectable medications that temporarily shut down estrogen production by the ovaries, effectively making the body postmenopausal so that an AI can do its job. A meta-analysis of 15,000 women across 25 trials found that adding ovarian suppression improved 15-year recurrence risk by 12.1% and reduced breast cancer mortality by 8.0%.
How Long Treatment Lasts
The standard course of hormone therapy is five years, but many women benefit from continuing longer. How long depends on your risk level.
For women with node-negative disease or only one to three positive lymph nodes, five to seven years of an aromatase inhibitor is generally considered optimal. Women with four or more positive lymph nodes are more likely to benefit from extending treatment to a full 10 years. The logic is straightforward: a large meta-analysis found that the absolute reduction in recurrence from extended therapy ranged from 1.1% for node-negative disease to 7.7% for node-positive disease. The benefit grows with the amount of cancer originally present.
The landmark ATLAS trial provided the strongest evidence for extending tamoxifen to 10 years. Women who continued tamoxifen had a recurrence rate of 21.4% over years 5 through 14, compared to 25.1% for those who stopped at five years. Breast cancer mortality dropped from 15.0% to 12.2%. Notably, most of the survival benefit appeared after year 9, suggesting the drug’s protective effect compounds over time. Recurrence risk dropped by 25% during the later years of treatment compared to women who stopped earlier.
For premenopausal women, the ASTRRA trial found that adding just two years of ovarian suppression to five years of tamoxifen improved 10-year disease-free survival from 75.9% to 83.7%.
Genomic Tests Can Refine Your Treatment Plan
If you have early-stage, hormone receptor-positive breast cancer, your oncologist may order a genomic test on your tumor tissue. Tests like Oncotype DX, EndoPredict, and Prosigna analyze gene activity in the tumor to estimate how likely it is to come back. The majority of women with early hormone receptor-positive breast cancer will not experience a recurrence with five years of hormone therapy alone. These tests help identify who falls into that favorable group and can safely skip chemotherapy, and who has a higher-risk tumor that warrants more aggressive treatment.
Genomic tests can also help guide decisions about extending hormone therapy beyond five years. The Breast Cancer Index, for example, evaluates both how fast the cancer was growing and how it responds to estrogen signaling, giving your care team more information about whether the extra years of treatment are worth the side effects for you specifically.
Combination Therapy for Advanced Disease
When breast cancer has spread beyond the breast or come back after initial treatment, hormone therapy is often combined with a class of targeted drugs called CDK4/6 inhibitors. These oral medications block proteins that help cancer cells divide, and when paired with hormone therapy, they slow disease progression significantly.
A pooled FDA analysis of nearly 2,000 patients with advanced hormone receptor-positive breast cancer found that adding a CDK4/6 inhibitor to fulvestrant improved overall survival across virtually all patient subgroups. For women receiving it as a second-line treatment or later, the median survival advantage was 7.1 months. These combinations have become standard first- or second-line treatment for metastatic hormone receptor-positive breast cancer.
Side Effects Differ Between Drug Classes
Tamoxifen and aromatase inhibitors have distinct side effect profiles, and this often factors into which therapy works best for a given person over the long term.
Tamoxifen commonly causes hot flashes, vaginal dryness, and mood changes. Because it mimics estrogen in the uterus, it slightly increases the risk of endometrial cancer and blood clots. On the positive side, its estrogen-like effects on bone actually help preserve bone density, which can be an advantage for women already at risk for osteoporosis.
Aromatase inhibitors, by contrast, strip estrogen from the entire body. This makes joint pain and stiffness one of the most common complaints, affecting a significant number of women on these drugs. AIs also accelerate bone loss, increasing the risk of fractures. Women on long-term AI therapy often need bone density monitoring and may take bone-protective medications alongside their cancer treatment. AIs do not carry the uterine or clotting risks associated with tamoxifen.
Ovarian function suppression adds its own layer of side effects, essentially inducing menopause in premenopausal women. Hot flashes, sleep disruption, and loss of bone density are common. For younger women, these side effects can be particularly disruptive to quality of life, which is why the decision to add ovarian suppression is typically reserved for higher-risk disease where the survival benefit clearly outweighs the burden.
Treatment tolerability matters. Guidelines from major oncology organizations explicitly factor in how well a woman is handling side effects when deciding whether to continue or extend therapy. A drug that works on paper but causes someone to stop taking it provides no benefit at all.